Advertisement

Prognostic Value of Galectin Expression in Patients with Breast Cancer: Systematic Review and Meta-Analysis

Published:December 29, 2021DOI:https://doi.org/10.1016/j.clbc.2021.12.011

      Abstract

      Galectins are a family of proteins with affinity for β-galactosides and their expression correlates with overall survival (OS) in several cancers. However, in breast cancer their prognostic potential is unclear. In this study we performed a meta-analysis to clarify the prognostic value of galectin expression in breast cancer and to identify sources of heterogeneity. For this purpose, we performed a search of related publications in PubMed, Central-Conchrane, Web of Science database, OVID-EMBASE, Scope and EBSCOhost until November 2021.Thirteen articles were included with a total of 2700 patients. High galectin expression was found not to correlate with OS in breast cancer (HR = 1.11, 95% CI 0.93–1.31). In the case of galectin-3, correlation with OS was observed when performing subgroup analysis by cellular localization (HR = 0.59, 95% CI 0.36–0.94 for cytoplasmic and HR = 1.82, 95% CI 1.00–3.29 for cytoplasmic plus nuclear). Galectin-7 correlates with DFS/PFS/DSS (HR = 2.43; 95% CI 1.36–4.31). Finally, galectin-3 correlates with some clinicopathological features such as lymph node metastasis, estrogen receptor expression and age. In conclusion, galectin-3 correlates with OS in breast cancer when cellular localization is considered while galectin-7 correlates with DFS/PFS/DSS. The cellular localization of galectins should be as fundamental aspect to be determined in future studies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mattiuzzi C
        • Lippi G
        Current cancer epidemiology.
        J Epidemiol Glob Health. 2019; 9: 217-222https://doi.org/10.2991/jegh.k.191008.001
        • Coughlin SS
        Epidemiology of breast cancer in women.
        Adv Exp Med Biol. 2019; 1152: 9-29https://doi.org/10.1007/978-3-030-20301-6_2
        • Delacour D
        • Koch A
        • Jacob R
        The role of galectins in protein trafficking.
        Traffic. 2009; 10: 1405-1413https://doi.org/10.1111/j.1600-0854.2009.00960.x
        • Nio-Kobayashi J
        Tissue- and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and disease.
        Anat Sci Int. 2017; 92: 25-36https://doi.org/10.1007/s12565-016-0366-6
        • Funasaka T
        • Raz A
        • Nangia-Makker P
        Nuclear transport of galectin-3 and its therapeutic implications.
        Semin Cancer Biol. 2014; 27: 30-38https://doi.org/10.1016/j.semcancer.2014.03.004
        • Wang L
        • Zhao Y
        • Wang Y
        • Wu X
        The Role of galectins in cervical cancer biology and progression.
        Biomed Res Int. 2018; 20182175927https://doi.org/10.1155/2018/2175927
        • Nangia-Makker P
        • Hogan V
        • Raz A
        Galectin-3 and cancer stemness.
        Glycobiology. 2018; 28: 172-181https://doi.org/10.1093/glycob/cwy001
        • Yasinska IM
        • Sakhnevych SS
        • Pavlova L
        • et al.
        The TiM-3-galectin-9 pathway and its regulatory mechanisms in human breast cancer.
        Front Immunol. 2019; 10: 1594https://doi.org/10.3389/fimmu.2019.01594
        • Reynolds NM
        • Mohammadalipour A
        • Hall CR
        • Asghari Adib A
        • Farnoud AM
        • Burdick MM
        Galectin-1 influences breast cancer cell adhesion to e-selectin via ligand intermediaries.
        Cell Mol Bioeng. 2018; 11: 37-52https://doi.org/10.1007/s12195-017-0512-9
        • Dalotto-Moreno T
        • Croci DO
        • Cerliani JP
        • et al.
        Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease.
        Cancer Res. 2013; 73: 1107-1117https://doi.org/10.1158/0008-5472.CAN-12-2418
        • Song L
        • Tang J
        • Owusu L
        • Sun MZ
        • Wu J
        • Zhang J
        Galectin-3 in cancer.
        Clin Chim Acta. 2014; 431: 185-191https://doi.org/10.1016/j.cca.2014.01.019
        • Moon BK
        • Lee YJ
        • Battle P
        • Jessup JM
        • Raz A
        • Kim HR
        Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis.
        Am J Pathol. 2001; 159: 1055-1060https://doi.org/10.1016/S0002-9440(10)61780-4
        • Song YK
        • Billiar TR
        • Lee YJ
        Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide.
        Am J Pathol. 2002; 160: 1069-1075https://doi.org/10.1016/S0002-9440(10)64927-9
        • Wang L
        • Li YS
        • Yu LG
        • et al.
        Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression.
        Biochem Pharmacol. 2020; 178: 114113https://doi.org/10.1016/j.bcp.2020.114113
        • Mammadova-Bach E
        • Gil-Pulido J
        • Sarukhanyan E
        • et al.
        Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3.
        Blood. 2020; 135: 1146-1160https://doi.org/10.1182/blood.2019002649
        • Pereira JX
        • dos Santos SN
        • Pereira TC
        • et al.
        Galectin-3 regulates the expression of tumor glycosaminoglycans and increases the metastatic potential of breast cancer.
        J Oncol. 2019; (Available at:): 1-16
        • Nangia-Makker P
        • Wang Y
        • Raz T
        • et al.
        Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer.
        Int J cancer. 2010; 127: 2530-2541https://doi.org/10.1002/ijc.25254
        • Gordon-Alonso M
        • Bruger AM
        • van der Bruggen P
        Extracellular galectins as controllers of cytokines in hematological cancer.
        Blood. 2018; 132: 484-491https://doi.org/10.1182/blood-2018-04-846014
        • Trebo A
        • Ditsch N
        • Kuhn C
        • et al.
        High galectin-7 and low galectin-8 expression and the combination of both are negative prognosticators for breast cancer patients.
        Cancers (Basel). 2020; 12 (Available at:): 953
        • Shafiq A
        • Moore J
        • Suleman A
        • Faiz S
        • Farooq O
        • Arshad A
        • et al.
        Elevated Soluble Galectin-3 as a Marker of Chemotherapy Efficacy in Breast Cancer Patients: A Prospective Study.
        Hindawi Limited, 2020https://doi.org/10.1155/2020/4824813
        • Shao Q
        • He J
        • Chen Z
        • Wu C
        Prognostic role of galectins expression in patients with hepatic cancer: a meta-analysis.
        Medicine (Baltimore). 2020; 99: e19622https://doi.org/10.1097/MD.0000000000019622
        • Sun Q
        • Zhang Y
        • Liu M
        • et al.
        Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis.
        Cancer Cell Int. 2019; 19: 309https://doi.org/10.1186/s12935-019-1025-5
        • Wu R
        • Wu T
        • Wang K
        • et al.
        Prognostic significance of galectin-1 expression in patients with cancer: a meta-analysis.
        Cancer Cell Int. 2018; 18: 108https://doi.org/10.1186/s12935-018-0607-y
        • Huang M
        • He J
        • Zhang W
        • Liu J
        Pooling analysis reveals that galectin-1 is a reliable prognostic biomarker in various cancers.
        J Cell Physiol. 2019; 234 (Available at:): 13788-13798
        • Moher D
        • Liberati A
        • Tetzlaff J
        • Altman DG
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        BMJ. 2009; 339: b2535https://doi.org/10.1136/bmj.b2535
        • Guyot P
        • Ades AE
        • Ouwens MJNM
        • Welton NJ
        Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
        BMC Med Res Methodol. 2012; 12: 9https://doi.org/10.1186/1471-2288-12-9
        • DerSimonian R
        • Laird N
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188https://doi.org/10.1016/0197-2456(86)90046-2
        • Mantel N
        • Haenszel W
        Statistical aspects of the analysis of data from retrospective studies of disease.
        J Natl Cancer Inst. 1959; 22: 719-748
        • Ilmer M
        • Mazurek N
        • Gilcrease MZMZ
        • et al.
        Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
        Breast Cancer Res. 2016; 18: 97https://doi.org/10.1186/s13058-016-0757-6
        • Yamaki S
        • Fujii T
        • Yajima R
        • et al.
        Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer.
        Surg Today. 2013; 43: 901-905https://doi.org/10.1007/s00595-012-0378-3
        • Moisa A
        • Fritz P
        • Eck A
        • et al.
        Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer.
        Anticancer Res. 2007; 27: 2131-2139
        • Irie A
        • Yamauchi A
        • Kontani K
        • et al.
        Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
        Clin Cancer Res. 2005; 11: 2962-2968https://doi.org/10.1158/1078-0432.CCR-04-0861
        • Grosset AA
        • Labrie M
        • Vladoiu MC
        • Yousef EM
        • Gaboury L
        • St-Pierre Y
        Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets.
        Oncotarget. 2016; 7: 18183-18203https://doi.org/10.18632/oncotarget.7784
        • Chen G
        • Zou Q
        • Yang Z
        [Expression of galectin-3 and Sambucus nigra agglutinin and its clinicopathological significance in benign and malignant lesions of breast].
        Zhong nan da xue xue bao Yi xue ban = J Cent South Univ Med Sci. 2010; 35: 584-589https://doi.org/10.3969/j.issn.1672-7347.2010.06.008
        • Jones C
        • Mackay A
        • Grigoriadis A
        • et al.
        Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer.
        Cancer Res. 2004; 64: 3037-3045https://doi.org/10.1158/0008-5472.can-03-2028
        • Logullo AFAF
        • Lopes ABGABG
        • Nonogaki S
        • et al.
        C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
        Oncol Rep. 2007; 18: 121-126https://doi.org/10.3892/or.18.1.121
        • Shafiq A
        • Moore J
        • Suleman A
        • et al.
        Elevated soluble galectin-3 as a marker of chemotherapy efficacy in breast cancer patients: a prospective study.
        Int J Breast Cancer. 2020; (Available at:): 1-11
        • Trebo A
        • Ditsch N
        • Kuhn C
        • et al.
        High galectin-7 and low galectin-8 expression and the combination of both are negative prognosticators for breast cancer patients.
        Cancers (Basel). 2020; 12: 953https://doi.org/10.3390/cancers12040953
        • Zhang H
        • Liang X
        • Duan C
        • Liu C
        • Zhao Z
        Galectin-3 as a marker and potential therapeutic target in breast cancer.
        PLoS One. 2014; 9: e103482https://doi.org/10.1371/journal.pone.0103482
        • Barrow H
        • Guo X
        • Wandall HHHH
        • et al.
        Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium.
        Clin cancer Res an Off J Am Assoc Cancer Res. 2011; 17: 7035-7046https://doi.org/10.1158/1078-0432.CCR-11-1462
        • Ju MH
        • Byun KD
        • Park EH
        • Lee JH
        • Han SH
        Association of galectin 9 expression with immune cell infiltration, programmed cell death ligand-1 expression, and patient’s clinical outcome in triple-negative breast cancer.
        Biomedicines. 2021; 9: 1383https://doi.org/10.3390/biomedicines9101383
        • Kaur M
        • Kaur T
        • Kamboj SS
        • Singh J
        Roles of Galectin-7 in Cancer.
        Asian Pac J Cancer Prev. 2016; 17: 455-461https://doi.org/10.7314/apjcp.2016.17.2.455
        • Wang K
        • Chen Z
        • Wu R
        • Yin J
        • Fan M
        • Xu X
        Prognostic role of high gal-9 expression in solid tumours: a meta-analysis.
        Cell Physiol Biochem. 2018; 45: 993-1002https://doi.org/10.1159/000487294
        • Wang C
        • Zhou X
        • Ma L
        • et al.
        Galectin-3 may serve as a marker for poor prognosis in colorectal cancer: a meta-analysis.
        Pathol Res Pract. 2019; 215152612https://doi.org/10.1016/j.prp.2019.152612
        • Wang Y
        • Liu S
        • Tian Y
        • et al.
        Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies.
        Cancer Cell Int. 2018; 18: 172https://doi.org/10.1186/s12935-018-0668-y
        • Zhou X
        • Sun L
        • Jing D
        • et al.
        Galectin-9 expression predicts favorable clinical outcome in solid tumors: a systematic review and meta-analysis.
        Front Physiol. 2018; 9: 452https://doi.org/10.3389/fphys.2018.00452
        • Song S
        • Mazurek N
        • Liu C
        • et al.
        Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity.
        Cancer Res. 2009; 69: 1343-1349https://doi.org/10.1158/0008-5472.CAN-08-4153
        • Shimura T
        • Takenaka Y
        • Tsutsumi S
        • Hogan V
        • Kikuchi A
        • Raz A
        Galectin-3, a novel binding partner of beta-catenin.
        Cancer Res. 2004; 64: 6363-6367https://doi.org/10.1158/0008-5472.CAN-04-1816
        • Liao DJ
        • Thakur A
        • Wu J
        • Biliran H
        • Sarkar FH
        Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy.
        Crit Rev Oncog. 2007; 13: 93-158https://doi.org/10.1615/critrevoncog.v13.i2.10
        • Mourad-Zeidan AA
        • Melnikova VO
        • Wang H
        • Raz A
        • Bar-Eli M
        Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry.
        Am J Pathol. 2008; 173: 1839-1852https://doi.org/10.2353/ajpath.2008.080380
        • Wang YG
        • Kim SJ
        • Baek JH
        • Lee HW
        • Jeong SY
        • Chun KH
        Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression.
        Exp Mol Med. 2012; 44: 387-393https://doi.org/10.3858/emm.2012.44.6.044
        • Cioca A
        • Muntean D
        • Bungardean C
        • Raica M
        • Cimpean AM
        Expression and distribution of galectin-3 in chromophobe and papillary carcinomas.
        Anticancer Res. 2018; 38: 259-263https://doi.org/10.21873/anticanres.12216
        • van den Brûle FA
        • Waltregny D
        • Liu FT
        • Castronovo V
        Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.
        Int J Cancer. 2000; 89: 361-367https://doi.org/10.1002/1097-0215(20000720)89:4<361::aid-ijc8>3.0.co;2-u
        • Honjo Y
        • Inohara H
        • Akahani S
        • et al.
        Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma.
        Clin cancer Res an Off J Am Assoc Cancer Res. 2000; 6: 4635-4640
        • Lotz MM
        • Andrews CW
        • Korzelius CA
        • et al.
        Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma.
        Proc Natl Acad Sci. 1993; 90: 3466-3470https://doi.org/10.1073/pnas.90.8.3466